Aflac Incorporated (AFLAC) - Q3 2005 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2005, and the nine-month period ended on the same date. Aflac Incorporated is a leading provider of supplemental health and life insurance, operating primarily through two segments: Aflac Japan and Aflac U.S.. The financial statements have been adjusted to reflect the adoption of SFAS 123R (Share-Based Payment) effective January 1, 2005.
Key Financial Metrics
| Metric (Nine Months Ended Sep 30, 2005) | 2005 (in millions) | 2004 (in millions) |
|---|---|---|
| Total Revenues | $10,796 | $9,834 |
| Premiums | $9,058 | $8,363 |
| Net Investment Income | $1,554 | $1,448 |
| Realized Investment Gains | $155 | ($7) |
| Net Earnings | $1,119 | $856 |
| Diluted EPS | $2.20 | $1.65 |
| Cash Flow from Operations | $3,464 | $3,530 |
| Total Assets | $57,453 | $59,326 |
| Notes Payable (Debt) | $1,700 | $1,429 |
| Shareholders' Equity | $8,006 | $7,576 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9.8% year-over-year, driven by a 8.3% increase in premiums and a 7.3% increase in net investment income.
- Profitability Surge: Net earnings rose 30.7% to $1.119 billion. This was significantly aided by realized investment gains of $155 million in 2005, compared to a loss of $7 million in 2004, primarily due to bond swap executions.
- Segment Performance:
- Aflac Japan: Pretax operating earnings increased 15.0% to $1.178 billion. Premium income grew 7.5% in dollars (6.4% in yen). Sales of medical products (EVER line) rose 31.7% in the quarter.
- Aflac U.S.: Pretax operating earnings increased 7.6% to $396 million. Premium income grew 10.5%. Sales were impacted by Hurricanes Katrina and Rita but still rose 10.0% in the third quarter.
- Foreign Currency Impact: The yen weakened to 113.19 per dollar (from 104.21 at year-end 2004), reducing reported assets and liabilities by approximately $3.8 billion and $3.7 billion, respectively, compared to prior year exchange rates.
- Nonrecurring Items: A $34 million benefit was recognized from the release of a valuation allowance for deferred tax assets related to the Parent Company's nonlife operating losses.
Guidance, Outlook, and Risks
- Earnings Guidance: Management maintains its 2005 objective of achieving net earnings per diluted share of at least $2.56 (14.8% growth over 2004), assuming no impact from foreign currency translation, realized investment gains/losses, or nonrecurring items. Management expects to meet or exceed this objective.
- Future Growth Targets: Objectives for 2006 and 2007 are 15% and 13-16% growth in net earnings per diluted share, respectively, based on the same assumptions.
- Key Risks:
- Currency Fluctuation: Significant exposure to yen/dollar exchange rates, which affects reported earnings and balance sheet values.
- Investment Risks: Exposure to interest rate changes and credit quality of privately issued securities (67.1% of debt portfolio).
- Operational Risks: Dependence on sales force recruitment and retention; potential for increased claims due to morbidity/mortality deviations.
- Regulatory: Restrictions on repatriating profits from Japan and changes in tax laws.
- Unusual Items: The filing notes that realized investment gains are not predictable and are excluded from earnings projections. The impact of SFAS 133 (derivatives) is also excluded from guidance.
Investor Verification Checklist
- Verify the sustainability of the realized investment gains ($155M) which drove a significant portion of the earnings increase, as these are excluded from future guidance.
- Monitor the yen/dollar exchange rate, as a weaker yen significantly suppresses reported dollar earnings and asset values for the Japan segment.
- Review the sales mix shift in Japan, specifically the decline in Rider MAX sales versus the growth in medical products (EVER), to assess long-term premium growth stability.
- Assess the impact of Hurricanes Katrina and Rita on Aflac U.S. persistency and claims in the fourth quarter of 2005 and first quarter of 2006, following the expiration of grace periods.
- Confirm the status of the share repurchase program, with approximately 19 million shares remaining available for purchase as of September 30, 2005.